» Articles » PMID: 36699264

Circulating FK506 Binding Protein 51 MRNA Expression in Patients with Pituitary Adenomas

Overview
Journal Heliyon
Specialty Social Sciences
Date 2023 Jan 26
PMID 36699264
Authors
Affiliations
Soon will be listed here.
Abstract

Background: FK506 binding protein 51 (FKBP5) is a co-chaperone regulator of the glucocorticoid receptor (GR). Recent studies have reported increased FKBP5 mRNA in the circulation from patients with Cushing disease (CD) which returned to comparable levels seen in healthy controls following successful -nasal -sphenoidal (TNTS) surgical corticotroph tumor removal. However, the expression of circulating FKBP5 mRNA levels in other pituitary tumor subtypes and its specificity to corticotroph tumors is unknown.

Methods: Pre-operative blood was collected from consecutive patients undergoing TNTS for pituitary tumors (n = 57) at our center between 2015 and 2019. Total RNA was isolated from whole blood using RiboPure blood RNA isolation kit and real-time qPCR was used to quantitate circulating FKBP5 mRNA expression.

Results: Consistent with the prior report, higher circulating FKBP5 mRNA levels were observed in 20 patients with CD prior to surgical tumor removal, compared to 21 healthy controls (p < 0.0005) and compared to 8 patients harboring gonadotroph pituitary tumors (p < 0.05) and 6 patients with silent corticotroph pituitary tumors (p < 0.05). However, circulating FKBP5 mRNA levels were higher in 10 patients with prolactin (PRL)-secreting pituitary tumors compared to healthy controls (p < 0.05), and did not differ between patients with CD and patients with growth hormone secreting tumors (GH-omas).

Conclusions: Although we confirm that circulating FKBP5 mRNA is higher in patients with corticotroph tumors compared to healthy subjects, measurement of circulating FKBP5 does not appear to be helpful to distinguish corticotroph tumors from other pituitary tumor sub-types.

References
1.
Rao S, Yao Y, Ryan J, Li T, Wang D, Zheng C . Common variants in FKBP5 gene and major depressive disorder (MDD) susceptibility: a comprehensive meta-analysis. Sci Rep. 2016; 6:32687. PMC: 5013409. DOI: 10.1038/srep32687. View

2.
Binder E, Salyakina D, Lichtner P, Wochnik G, Ising M, Putz B . Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004; 36(12):1319-25. DOI: 10.1038/ng1479. View

3.
Binder E, Bradley R, Liu W, Epstein M, Deveau T, Mercer K . Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA. 2008; 299(11):1291-305. PMC: 2441757. DOI: 10.1001/jama.299.11.1291. View

4.
Nieman L, Biller B, Findling J, Newell-Price J, Savage M, Stewart P . The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93(5):1526-40. PMC: 2386281. DOI: 10.1210/jc.2008-0125. View

5.
Fujii T, Ota M, Hori H, Hattori K, Teraishi T, Matsuo J . The common functional FKBP5 variant rs1360780 is associated with altered cognitive function in aged individuals. Sci Rep. 2014; 4:6696. PMC: 4204028. DOI: 10.1038/srep06696. View